AbCellera Biologics Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
ABCL$12.50+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| December 31, 2024 | March 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $156,325 | $159,266 |
| Marketable securities | 469,289 | 446,000 |
| Total cash, cash equivalents, and marketable securities | 625,614 | 605,266 |
| Accounts and accrued receivable | 33,616 | 40,005 |
| Restricted cash | 25,000 | 25,000 |
| Other current assets | 67,140 | 94,707 |
| Total current assets | 751,370 | 764,978 |
| Long-term assets: | ||
| Property and equipment, net | 340,429 | 347,102 |
| Intangible assets, net | 42,113 | 41,192 |
| Goodwill | 47,806 | 47,806 |
| Investments in equity accounted investees | 82,297 | 81,567 |
| Other long-term assets | 96,538 | 61,563 |
| Total long-term assets | 609,183 | 579,230 |
| Total assets | $1,360,553 | $1,344,208 |
| Liabilities and shareholders' equity | ||
| Current liabilities: | ||
| Accounts payable and other current liabilities | $55,004 | $47,840 |
| Contingent consideration payable | 8,087 | 8,771 |
| Deferred revenue | 13,521 | 18,785 |
| Total current liabilities | 76,612 | 75,396 |
| Long-term liabilities: | ||
| Operating lease liability | 60,743 | 63,210 |
| Deferred revenue | 5,700 | 13,750 |
| Deferred government contributions | 149,893 | 157,193 |
| Deferred tax liability | 10,052 | 10,053 |
| Other long-term liabilities | 1,469 | 1,624 |
| Total long-term liabilities | 227,857 | 245,830 |
| Total liabilities | 304,469 | 321,226 |
| Commitments and contingencies | ||
| Shareholders' equity: | ||
| Common shares: no par value, unlimited authorized shares at December 31, 2024 and March 31, 2025: 295,757,002 and 298,355,752 shares issued and outstanding at December 31, 2024 and March 31, 2025, respectively | 777,171 | 790,068 |
| Additional paid-in capital | 166,361 | 168,603 |
| Accumulated other comprehensive loss | (4,378) | (6,998) |
| Accumulated earnings | 116,930 | 71,309 |
| Total shareholders' equity | 1,056,084 | 1,022,982 |
| Total liabilities and shareholders' equity | $1,360,553 | $1,344,208 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.